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Abstract Growth factors or serum can induce transcription and translation of a dual specificity MAP (mitogen-activated protein) kinase phosphat- 
ase, MKP-1 (MAP kinase phosphatase-1). The role of induction of MKP-1 (formerly 3CH134) in the rapid phase of MAP kinase deactivation was 
studied in rat pheochromocytoma (PC12) cells. MAP kinase was nearly completely deactivated in PC12 cells by 10 min after stimulation with 
epidermal growth factor (EGF) whereas MAP kinase activity remained elevated at 30% of the maximal response after stimulation with nerve growth 
factor. Protocols for treating cells with actinomycin D and cycloheximide were established that eliminate detection of MKP-1 mRNA and protein 
in PC 12 cells. Treatment of PC12 cells with actinomycin D and cycloheximide id not affect he rapid eactivation of MAP kinase. Thus, the rapid 
phase of MAP kinase deactivation i PC12 cells is not dependent on the induction of the MAP kinase phosphatase MKF-1. 
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1. Introduction 
MAP kinases (also known as ERKs) are activated by dual 
tyrosine and threonine phosphorylations in response to diverse 
extracellular signals in many cell types and contexts (reviewed 
in [l]). Two closely related, and so-far apparently redundant, 
MAP kinase isoforms p42-*‘/ERK2 and p44m”pk/ERK1 have 
been studied most intensely. Each MAP kinase is activated by 
phosphorylations of the regulatory threonine and tyrosine res- 
idues in a conserved TEY motif, catalyzed by MAP kinase 
kinases [2]. The mechanisms that determine the kinetics of 
activation and deactivation of MAP kinase are incompletely 
understood. Some growth factors or hormones, such as insulin 
in adipocytes [3,4], or EGF in PC12 cells ([5]; this report), 
produce a rapid and transient activation which peaks at 2-10 
min. A biphasic response with a rapid, transient activation 
phase followed by a second, more prolonged activation phase 
was observed in lung fibroblast CCL39 cells stimulated with 
thrombin [6]. In contrast, serum-stimulated NIH 3T3 fibro- 
blasts contain elevated MAP kinase activity which does not 
significantly decline for up to 60 min ([7]; data not shown). 
These differences in activation kinetics reflect differences in 
usage of the multiplicity of operative activation and deactiva- 
tion pathways. 
Deactivation of MAP kinase can be accomplished by 
dephosphorylation of either the regulatory phosphothreonine 
residue or the phosphotyrosine residue, or both. Two protein 
phosphatases that areeffective in vitro are the protein-serine/ 
threonine phosphatase 2A and the protein-tyrosine phosphat- 
ase CD45 [8]. Recently, several laboratories have identified a 
family of inducible protein phosphatases with dual protein- 
tyrosinelthreonine specificity and selectivity for MAP kinase 
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[7,9-l 11. MKP-1 was identified as the product of an immediate 
early gene 3CH134 induced by sefzlfn in mouse Balblc 3T3 cells 
[IO]. The human homolog of MKP-1 (97% identity) was found 
independently as the product of a stress-induced mRNA 
(CLlOO) in fibroblasts [ll]. PAC-1, a distinct but MKP-1 re- 
lated enzyme, has been characterized as a T-11 specific, induc- 
ible MAP kinase phosphatase localized to the nucleus [12]. 
Induction of MKP-1 is likely to be an important physiological 
mechanism for deactivation of MAP kinase [7,13]. Notonly 
does MICP-1 exhibit specificity for MAP kinase as a substrate 
but MI@-1 interacts sticiently strongly with MAP kinase to 
permit co-immunoprecipitation [7]. Treatment of cells with cy- 
cloheximide prolonged activation of MAP kinase in quiescent 
NIH 3T3 cells treated with serum [7]. However, sew causes 
a prolonged activation of MAP kinase in NIH 3T3 cells, with- 
out a rapid inactivation phase ([A; data not shown). Whether 
the phosphatase could be induced rapidly enough to account 
for the initial, rapid deactivation of MAP kinase that occurs 
within IO-15 min in other cells and contexts seemed doubtful 
to us. We report results of critical tests of this hypothesis for 
MAP kinase deactivation in PC 12 cells using actinomycin D 
and cycloheximide in combination to inhibit transcription and 
translation, respectively, of inducible protein phosphatases. 
The results demonstrate that induction of MKP-1 plays no role 
in the rapid, first phase of MAP kinase deactivation in PC12 
cells. 
2. Materials and methods 
2.1. Materials 
Rat pheochromocytoma cells (PC12 cells) were obtained from M. 
Cox and P. Maness (University of North Carolina, Chapel Hill, NC) 
who obtained them directly from L. Greene (Columbia University, New 
York, NY). Receptor grade mouse EGF was purchased from Collabo- 
rative Research, Bedford, MA; NGF was from Upstate Biotechnology 
(Lake Placid, NY). Anti-MAP kinase antibody (TRIO) recognizing 
p42mark was provided by M. Weber (Department of Microbiology). 
RPM1 1640 medium and fetal calf serum were from Gibco-BRL 
(Gaithersburg, MD). Actinomycin D, cycloheximide, and human 
placental type IV collagen (Sigma C-7521) were from Sigma-Aldrich 
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(St. Louis, MO). AfIinity-purified anti-peptide antibody recognizing 
MKP-1 was a aenerous ift from N. Tonks (Cold Snrina Harbor Lab- 
oratory, Cold %pring Harbor, NY). Sources of other reagents and 
proteins have been given [14]. 
2.2. Cell culture and kinuse assays 
PC12 cells were seeded equally in 60 mm tissue culture dishes coated 
with collagen and grown to contluence in RPM1 1640 media containing 
10% (v/v) horse serum (JRH Biosciences, Lenexa, KS), 5% (v/v) fetal 
calf serum, penicillin G (20 U/ml), and streptomycin (20 mg/ml). NIH 
3T3 cells were grown as described [7]. Prior to growth factor stimula- 
tion, cells were washed 2 times with RPM1 1640 and serum-starved for 
3-3.5 h in the same media. Following stimulation with NGF or EGF, 
plates were placed on ice, the media was rapidly aspirated, and the 
plates were washed with cold (4’C) phosphate buffered saline. Individ- 
ual plates were then processed for immune-complex kinase assays of 
MAP kinase as described [14]. MAP kinase kinase activity in the initial 
supematants was assayed using homogeneous K52R protein as sub- 
strate as described [14]. 
Where used, actinomycin D (2 PM, final) was added at the onset of 
serum-serum starvation (3.5 h prior to NGF or EGF treatments). 
Cycloheximide (140 PM, final) was added during the last 30 min of 
serum-starvation. 
2.3. Northern analysis 
Total cellular RNA was isolated from individual 100 mm plates of 
PC12 or NIH 3T3 cells by a single-step method [15] using RNA STAT- 
60 reagent (Tel-Test ‘B’ Inc., Friendswood, TX). Total RNA (20 pg) 
from each sample was separated by electrophoresis on formaldehyde- 
agarose gels (1% gel) and transferred to nitrocelhtlose for probing with 
the full-length [32P]cDNA for MKP-1 (3CHl34) [lo], labeled by the 
random primer method. Hybridization and washing conditions were as 
described [16]. 
2.4. 35S-L&eling and immunoprecipitation of MKP-I 
Cells were washed in serum-free Dulbecco’s modified Eagle’s media 
containing no methionine, cystine, cysteine, or glutamine (ICN, Costa 
Mesa, CA) and then serum-starved in the same media for 3 h. 
[3SS]Methionine/[3SSlcysteine (Tran3sS-label (ICN)) was added (0.2 mCi/ 
ml, Iinal) after 1 h of serum-starvation. Additions of actinomycin D and 
cycloheximide were made as above. After growth-factor treatment, cells 
were lysed and processed for immunoprecipitation of MKP-1 with an 
antibody raised against a synthetic peptide from the carboxyl-terminus 
[fl, or with an antibody raised against an E. coli expressed recombinant 
MKP-1 [lo] according to the protocol described [7,10]. Immunoprecip- 
itated proteins were separated by SDS/polyacrylamide gel electrophore- 
sis (10% gel) and detected by fluorography using Amplify (Amersham) 
according to the manufacturer’s instructions. 
3. Rewlts and discussion 
When PC12 cells were serum-starved and stimulated with 
either EGF or NGF, rapid activation of MAP kinase kinase 
and MAP kinase were observed (Fig. 1). Deactivation of MAP 
kinase kinase and MAP kinase in response to either growth 
factor also occurred rapidly. Deactivation of MAP kinase ki- 
nase preceded eactivation of MAP kinase. Both MAP kinase 
and MAP kinase kinase activities were reduced by more than 
50% of the peak value within 10 mm. Whereas MAP kinase and 
MAP kinase kinase activities returned to basal values following 
EGF-treatment, MAP kinase and MAP kinase kinase activities 
persisted at -2O-30% of the maximal response following NGF- 
treatment. These differences between EGF and NGF responses 
are qualitatively similar to previous reports [5,171. Because 
deactivation of EGF-stimulated MAP kinase activity was 
nearly complete, further experiments were focused on the EGF 
response. 
To investigate the contribution of inducible protein 
phosphatases to the rapid deactivation of MAP kinase in PC12 
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Fig. 1. Time courses of activation of MAP kinase kinase and MAP 
kinase in PC12 cells. PC12 cells were starved of serum and treated with 
or without actinomycin D (ACT) and cycloheximide (CHX) as de- 
scribed in section 2. Cells were stimulated with either EGF (150 @ml) 
or NGF (75 ng/ml) for the indicated times and processed for determina- 
tion of MAP kinase activity by an immune-complex kinase assay 
method and for determination of MAP kinase kinase activity by phos- 
phorylation of a kinase-defective mutant (K52R) of p42MAPK. (A) MAP 
kinase activities in PC12 cells. The data represent the means of triplicate 
samples which differed by less than 10%. (B) MAP kinase kinase activ- 
ities in PC12 cells. MAP kinase kinase activities were measured by 
phosphorylation of K52R protein and were quantitated with a 
PhosphorImager (Molecular Dynamics). Data were presented as rela- 
tive activity in reference to the maximum MAP kinase kinase activity 
of each treatment. 
cells, conditions were used to inhibit transcription and transla- 
tion of MKP-1. Both MKP-1 mRNA [18] and protein [lo] have 
been demonstrated to undergo rapid degradation in the ab- 
sence of new synthesis. The half-lives of MKP-1 mRNA and 
protein determined in mouse Balb/c 3T3 fibroblasts were- 15-30 
min and -40 min, respectively [10,18]. Cells were treated with 
2 PM actinomycin D for 3 h in the absence of cycloheximide 
to block synthesis of MKP-1 mRNA and to allow degradation 
of existing MKP-1 mRNA [10,18]. As a consequence, MKP-1 
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Fig. 2. 
of preparations from PC12 cells or NIH 3T3 cells were separated on 
a formaldehyd*l 8 agarose gel containing ethidium bromide (0.5 pugl 
ml). After electrophoresis, the gel was photographed(B), and RNA was 
transferred to a nitrocellulose filter. The fllter was probed with a ‘*P- 
labeled full-length MKP-l(3CHl34) cDNA (A). Lanes l-3, RNA from 
serum-starved PC12 cells left unstimulated (lane 1), or stimulated with 
EGF (150 &ml) for 10 min (lane 2) or 60 min (lane 3). Lanes 4-6, RNA 
from actinomycin D- and cycloheximide-treated, serum-starved PC12 
cells left unstimulated (lane 4), or stimulated with EGF for 10 min (lane 
5) or 60 min (lane 6). Lanes 7-10, RNA from serum-starved NIH 3T3 
cells (lane 7), and serum-starved NIH 3T3 cells stimulated with fetal calf 
serum (20% v/v, final) for 40 min (lane 8), 60 min (lane 9) or 90 min 
(lane 10). Arrowhead indicates the MKP-1 mRNA. The rat MKP-1 
cDNA has been cloned from a rat brain library and deposited in the 
GenBank data base (Qian, Z., Gilbert, M.E. and Kandel, E.R, acces- 
sion number UO2553). The nucleotide seauence of the rat MKP-1 
cDNA is 93% identical to that of the mouse MKP-1 cDNA used as 
probe. 
protein should also be degraded. Cycloheximide (140 PM) was 
added to actinomycin D-treated cells during the final 30 min 
of serum-starvation to inhibit translation of any mRNA that 
might have remained. 
Northern analyses were performed to determine the effects 
of actinomcyin D and cycloheximide treatments on MKP-1 
mRNA in mouse NIH-3T3 and rat PC-12 cells (Fig. 2). Rat and 
mouse MKP-I proteins are 98% identical. Low levels of MKP-1 
mRNA were detected in serum-starved PC12 cells (lane 1) and 
NIH 3T3 cells (lane 7). As reported previously [7,10], serum- 
treatment induced expression of MKP-1 mRNA in NIH 3T3 
cells (lanes S-lo), validating our methodologies. No apprecia- 
ble increase in MKP-1 mRNA was detected in serum-starved 
PC12 cells treated with EGF (150 &ml) for 10 or 60 min (lanes 
2, 3). Importantly, no MKP-I mRNA was detected in PC12 
cells treated with actinomycin D and cycloheximide even fol- 
lowing treatment with EGF (lanes 4-6). 
Immunoprecipitations from 35S-labeled cells were performed 
to determine the effects of actinomycin D and cycloheximide 
treatments on the levels of MKP-I protein in PC12 cells (Fig. 
3). Immunoprecipitations were performed with affiity-puri- 
fied antibodies prepared against a synthetic MKP-1 peptide [7] 
(Fig. 3) and against recombinant MKP-1 protein (data not 
shown). Similar results were obtained with both antibodies. 
Little MKP-I protein was detected in serum-starved NIH 3T3 
cells (lane 3). Serum-treatment (1 h) of NIH 3T3 cells caused 
a substantial induction of MKP-1 protein (lane 4 vs. lane 3). 
The 40 kDa protein is identified as MKP- 1 based on: (i) recog 
nition by both previously characterized antibodies; (ii) appro- 
priate mobility; and (iii) especially induction by serum as de- 
scribed by Sun et al. [7J. MICP-1 was detected in PC-12 cells that 
have been treated with EGF (150 ng/ml, 15 min) (lane 1). 
Importantly, no MKP-1 protein could be detected in PC12 cells 
treated with actinomycin D and cycloheximide (lane 2), imply 
ing that the protein was depleted in concert with depletion of 
MKP-1 mRNA, although it is possible that trace amounts of 
MKP-1 protein below a threshold of detection are still present. 
To investigate the contribution of inducible phosphatases to 
the rapid deactivation of MAP kinase, PC12 cells were treated 
with actinomycin D and cycloheximide as above prior to stim- 
ulation with EGF and assay of MAP kinase kinase (Fig. 1B) 
and MAP kinase (Fig. 1A). Actinomycin D and cycloheximide 
pretreatment had no effect on the activation of MAP kinase 
kinase or MAP kinase (Fig, 1B). Under conditions in which no 
MKP-1 mRNA and protein were detectable (Fig. 2), deactiva- 
tion of MAP kinase was not affected. The time courses for 
MAP kinase activity with and without treatment with actino- 
mycin D and cycloheximide were nearly superimposable. 
We conclude from these experiments that the induction of 
the dual specificity protein-tyrosine/threonine phosphatase 
MKP-1 is not the principal mechanism accounting for the rapid 
deactivation of MAP kinase in PC12 cells. This conclusion 
seems unequivocal. Furthermore, the conditions used would be 
likely to block induction of any unidentified inducible protein 
phosphatase(s) in PC12 cells, should any exist, provided they 
have similar turn-over rates. Our experiments were not de- 
Fig. 3. Analysis of MKP-1 protein. PC12 cells or NIH 3T3 cells were 
metabolically labeled with [‘?S]methionine/cysteine a d stimulated with 
growth factors as described in section 2. MKP-1 was immunoprecipi- 
tated with an anti-MKP-I-neutide antibody 171. The antibodv-antigen 
complexes were isolated by protein A-agarose-and washed eight times 
with the specified lysis buffer [7J Lanes 1, serum-starved PC12 cells 
stimulated with EGF (150 &ml, 15 min); lanes 2, serum-starved PC12 
cells that were treated with actinomycin D/cycloheximide and stimu- 
lated with EGF; lanes 3, serum-starved NIH 3T3 cells; lanes 4, serum- 
starved NIH 3T3 cells that were stimulated with dialyzed calf-serum 
(20% v/v, 60 min). Lane 5, NIH 3T3 cell lysate were prepared as in lane 
4 and incubated with protein A-agarose without antibody. Arrowheads 
indicate MKP-1 protein bands. Arrow indicates a prominent ‘*S-la- 
beled protein in PC12 cells which binds nonspecifically to protein A- 
agarose. The intensity of this 3SS-labeled band is reduced in lane 2 due 
to the inhibition of protein synthesis by actinomycin D/cycloheximide. 
This nonspecific, 35S-labeled protein has been observed previously in 
immunoprecipitates from Balb/c 3T3 cells and rat vascular smooth 
muscle cells [10,22]. 
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signed to identify the responsible MAP kinase phosphatase(s), 
only to test the importance of induction of MKP-1 to the rapid 
deactivation of MAP kinase in PC12 cells. While induction of 
MKP-1 is not required for the rapid deactivation, it is possible 
that MKP-1 basally expressed in PC12 cells is suf8cient for 
rapid deactivation. However, the amount of MKP-1 expressed 
basally would have to be in considerable xcess because signif- 
icant depletion of MRP-1 protein by actinomycin and cyclo- 
heximide did not affect the kinetics of deactivation. It seems 
more likely that other protein phosphatases than MKP-1 con- 
tribute to the rapid deactivation of MAP kinase in PC12 cells. 
Phosphatase 2A catalytic subunit can inactivate MAP kinase 
in vitro [8] and Ser/Thr phosphatases are still tenable candi- 
dates for MAP kinase phosphatases in vivo. Phosphatase 2A 
has been strongly implicated in regulation of the MAP kinase 
pathway in vivo by the finding that SV40 small T antigen causes 
up-regulation of both MAP kinase kinase and MAP kinase 
activities in CV-1 cells (19). Evidence for a tyrosine specific 
MAP kinase phosphatase in interphase xtracts prepared from 
Xenopus eggs has been obtained by Sarevic et al. [20]. However, 
the Xenopus protein-tyrosine phosphatase failed to bind to a 
column of thio-phosphorylated MAP kinase whereas an oka- 
daic-sensitive MAP kinase phosphatase was retained by the 
column. 
MAP kinase activity in vivo is determined by the relative 
activities of the immediate upstream activators, the MAP ki- 
nase kinases, and the MAP kinase phosphatase(s). While differ- 
ences in phosphatase regulation are a possible explanation for 
the differences in MAP kinase activation observed with NGF- 
versus EGF-stimulation, the data of Muroya et al. [21] on Ras 
activation in PC12 cells is consistent with the steady-state l vel 
of Ras-GTP being the major determinant of MAP kinase activ- 
ity. The temporal profiles of EGF- and NGF-stimulated MAP 
kinase activation (Fig. 1A) and MAP kinase kinase (Fig. 1B) 
for PC12 cells are remarkably similar to temporal profiles of
EGF- and NGF-stimulated p21 Ras activation in PC12 cells 
(see Fig. 4 in [20]). Thus, there may be no need to invoke 
differences in downstream regulation to explain differences in 
the kinetics of activation of MAP kinase by NGF and EGF in 
PC12 cells. 
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